BloodSTOP® is a natural, biocompatible, non-irritating, animal-free material that adheres to a wound, absorbs blood, stops bleeding, and forms a protective layer to create an environment for wound healing.  Its water solubility allows it to be rinsed off without disruption to the clotted surface.

 

Executive Team

Vicky Feng, Chief Executive Officer and President

Vicky Feng founded LifeScience PLUS with a vision for next-generation medical products that aid medical professionals in administering care while improving patient recovery. She brings 16 years of computer industry and 9 years of medical industry entrepreneurial and management experience to the Company, guiding startups and maturing them into fully profitable enterprises.  One of her earliest ventures was in the PC industry where she was on the founding team and grew the company to $10 million in annual revenues in 3 years.  Ms. Feng holds a B.S. degree in Electrical Engineering from Beijing United University.

 

Wayne Korteweg, Chief Operating Officer

Mr. Korteweg has over thirty years of professional business experience in the medical field and possesses a depth of experience in design, manufacturing, sales, marketing and operations. Mr. Korteweg is the inventor of 5 patents for products in the areas of Neurology, Ophthalmology, Otolaryngology, OTC and Cosmetic markets. He has extensive experience working with medical professionals in the concept and design stages of product development. Mr. Korteweg founded and served as President and CEO of Ultracell Medical Technologies Inc., which manufactured, marketed, and sold surgical disposables to the Ophthalmology and Otolaryngology markets with branded as well as OEM and private label products. He later sold the company and become a full-time partner with LifeScience PLUS.

N. Scott Fine

Mr. Fine is an investment banker at Scarsdale Equities, an investment-banking firm located in New York City, and has been involved in corporate finance for over 30 years. Mr. Fine has focused his efforts and has worked or initiated several transactions in the healthcare and consumer products area, including the following: In healthcare Mr. Fine had advised Research Medical, a specialty medical device manufacturer, on a strategic equity alliance with The Tempo Group of Jakarta, Indonesia; Research Medical was subsequently bought by Baxter. He was the lead investment banker on the Initial Public Offering for Med-Design Corporation, a specialty medical device company, which was thereafter acquired by Specialized Health Products International, Inc.  Mr. Fine also was the lead investment banker for DermaSciencs, Inc., corporate focus being wound management.  He also advised on several funding transactions for Interleukin Genetics (AMEX ILI), leading to the consummation of an Equity Strategic Alliance with Alticor, an eight billion dollar privately held company.  Mr. Fine became a special internal advisor to The Tempo Group of Jakarta, Indonesia, one of Indonesia’s largest private groups, whose business focus is in healthcare and consumer products. Mr. Fine and his family, while working specifically for Tempo, resided in Jakarta for a period of two years. He also advised and was the lead banker on the Initial Public Offering of Green Mountain Coffee Roasters (NASDAO GMCR).  He and his firm, Fine Equities, also initiated and co-managed the Initial Public Offering of Central European Distribution Corporation, Inc. (NASDAQ CEDC), and currently sits as a member of their Board of Directors. Additionally, Mr. Fine sits on the Deans Advisory Board for The University of Connecticut’s Neag School of Education at Storrs, Connecticut.

James Pachence, Chief Scientific Officer

Dr. Pachence is a successful medical products executive with over 25 years experience with the management and development of entrepreneurial life sciences companies. Since July 2008, Dr. Pachence has been a managing director with Ridgeview Partners, a technology consulting group having an emphasis on new business development, in-licensing, technology assessment, financial modeling, and strategic analysis.  Most recently, Dr. Pachence was the president/CEO of Virium Pharmaceuticals, a specialty pharmaceuticals company focused on developing novel oncology drugs.  Virium had two products in Phase II clinical development, as well as a pipeline of earlier stage oncology drugs. The company was sold in April 2008 to Macrochem, a public company.

Dr. Pachence was Founder, President and Chief Scientific Officer of MediMatrix, Inc., which formed the basis of Integra LifeSciences, a public company focused on tissue repair.  He was Vice President of R&D while at Integra.  He was responsible for technology licensing, industrial and academic R&D, and product development and developed medical products for applications in general surgery, cardiovascular repair, neural repair, and cartilage repair.  Five of his projects at Integra led to significant commercial products.  His accomplishments include twenty-one patents, six commercial product introductions, development of more than 15 pre-clinical assessment programs, and development of eight clinical assessment programs.  His academic achievements include 50 major articles, 5 review articles, 6 book chapters, and over 80 presented papers. He is currently on the editorial board of the Journal for Biomedical Materials Research (a publication of the Society for Biomaterials).  Dr. Pachence holds a Ph.D. in Biophysics from the University of Pennsylvania (received in 1980, magna cum laude).

Mark Brenner, Chief Financial Officer

Mr. Brenner brings over 30 years experience in public accounting to LSP.  From 1976 to 1989, Mr. Brenner worked for BDO Seidman in New York achieving the position of Senior Manager.  At BDO he was responsible for audit and tax of major corporations, including involvement with public offerings.  From 1989 to 1997, Mr. Brenner was a Partner in Marden Harrison & Kreuter, LLP, a regional accounting firm located in Westchester, New York.  Since 19987, Mark as been the Chief Financia Officer for various entities involved in Real Estate Develoment and Venture Capital and advisor to a High Net Worth Individual.  Mark Brenner is a Certified Public Accountant and holds a B.S. in accounting from Brooklyn College.

 

David J. Ehnot, Senior VP, Sales and Marketing

Mr. Ehnot brings over twenty five years of sales and marketing experience in the medical device industry to LifeScience PLUS®.  Mr. Ehnot has worked for notable medical device companies including Olympus America and Boston Scientific. In addition, he is experienced in the area of emerging growth companies such as Vascular Solutions Inc., Kerberos Proximal Solutions, Inc. (acquired by Fox Hollow Technologies) and others.  His vast experience includes all surgical segments, interventional cardiology and radiology. Mr. Ehnot received his B.A. Degree from the University of Connecticut.

 

John O'Maley, VP, Sales and Marketing OTC/Consumer

Mr. O'Maley has over 30 years of consumer product goods sales and marketing experience in the food, drug and mass trade industries.  John helped develop and launch over 40 new product lines successfully including BreathRx Premium Oral Care (gaining distribution into 54,000 stores), Sinupret Children's Sinus Product (34,000 stores in year 1), MyClyns Germ Protection Spray (30,000 stores in 6 months), Ginsana Herbal Supplement (65,000 stores), Hollywood 24 Miracle Diet (25,000 stores), Atkins Answer Diet Video (40,000 stores in 4 months), EZ Grill Disposable Green Grill (24,000 stores in 5 months) and many more.  He was trained in leadership at West Point, the United States Military Academy.  He was also trained in sales, marketing, advertising and business development at Proctor & Gamble.  His military experience (Captain, Ranger, Airborne, US Army) and P&G classical training have been instrumental in generating outstanding results for each company for which John worked.

Audrey Vitale, Regulatory Affairs Specialist

Ms. Vitale has ten years of experience in medical device regulation, including product approvals in the US and EU, and quality system compliance with ISO 9001, ISO 13485, EU Medical Device Directive, and FDA Quality System Regulation.  Ms. Vitale has a B.S. in Materials Engineering from Rensselaer Polytechnic Institute, and is a member of the Regulatory Affairs Professional Society, with certification in US Regulatory Affairs.

 

 

 

Board of Directors

Vicky Feng, Chairman

Vicky Feng founded LifeScience PLUS with a vision for next-generation medical products that aid medical professionals in administering care while improving patient recovery. Serving as Chief Executive Officer and President, she brings 9 years of medical and 16 years of computer industry entrepreneurial and management experience to the Company, guiding startups and maturing them into fully profitable enterprises.  One of her earliest ventures was in the PC industry where she was on the founding team and grew the company to $10 million in annual revenues in 3 years.  Ms. Feng holds a B.S. degree in Electrical Engineering from Beijing United University.

 

Dr. Kenneth Robinson, M.DM.

Dr. Robinson specializes in Oral and Maxillofacial Surgery and has been in private practice for over thirty years. He has been honored as a Board Diplomat, American Board of Oral Surgery; Fellow, American Dental Society of Anesthesiology; Fellow, American Association of Oral and Maxillofacial Surgeons and a Diplomat of the National Dental Board of Anesthesiology. Dr. Robinson has authored numerous publications in leading dental and medical industry journals. He holds a M.D.M. degree from the University of Pennsylvania. 

 

 

James Little, Esquire

James Little has forty-five years of experience practicing corporate law during which time he has represented private business concerns throughout Silicon Valley. He has focused his firm’s practice on the formation and legal representation of growth companies. Mr. Little is a graduate of Harvard College and Stanford Law School.

 

 

 

N. Scott Fine

Mr. Fine is an investment banker at Scarsdale Equities, an investment-banking firm located in New York City, and has been involved in corporate finance for over 30 years. Mr. Fine has focused his efforts and has worked or initiated several transactions in the healthcare and consumer products area, including the following: In healthcare Mr. Fine had advised Research Medical, a specialty medical device manufacturer, on a strategic equity alliance with The Tempo Group of Jakarta, Indonesia; Research Medical was subsequently bought by Baxter. He was the lead investment banker on the Initial Public Offering for Med-Design Corporation, a specialty medical device company, which was thereafter acquired by Specialized Health Products International, Inc.  Mr. Fine also was the lead investment banker for DermaSciencs, Inc., corporate focus being wound management.  He also advised on several funding transactions for Interleukin Genetics (AMEX ILI), leading to the consummation of an Equity Strategic Alliance with Alticor, an eight billion dollar privately held company.  Mr. Fine became a special internal advisor to The Tempo Group of Jakarta, Indonesia, one of Indonesia’s largest private groups, whose business focus is in healthcare and consumer products. Mr. Fine and his family, while working specifically for Tempo, resided in Jakarta for a period of two years. He also advised and was the lead banker on the Initial Public Offering of Green Mountain Coffee Roasters (NASDAO GMCR).  He and his firm, Fine Equities, also initiated and co-managed the Initial Public Offering of Central European Distribution Corporation, Inc. (NASDAQ CEDC), and currently sits as a member of their Board of Directors. Additionally, Mr. Fine sits on the Deans Advisory Board for The University of Connecticut’s Neag School of Education at Storrs, Connecticut.

Jeffrey T. Barnes

Mr. Barnes has over 25 years of start-up, operating and investment experience in the life sciences and healthcare sectors.  In 9 years as a venture capitalist at Oxford Bioscience Partners, Mr. Barnes led the creation and expansion of the firm's investment program in medical devices and diagnostic instrumentation, establishing and overseeing investments in 18 portfolio companies.  Prior to Oxford, he worked at the investment banking firms of Needham & Co. and Robertson, Stephens & Co. coordinating the financing and merger activity of over 20 medical device and healthcare technology companies.  In addition, he has over 8 years of operating experience, including management positions in research and development, manufacturing, and marketing within the Medical Products Group of Hewlett-Packard Corp.

Mr. Barnes is a member of the Clinical Cardiology Council of the American Heart Association, the National Society of Professional Engineers, and the Association for the Advancement of Medical Instrumentation. He is a charter member of the Harvard-M.I.T. Health Sciences and Technology Advisory Council, and is on the Board of Advisors at the Duke University Center for Entrepreneurship and Innovation.  He has served on the Board of Directors of over 20 public and private healthcare technology companies, has been a co-founder of 5 medical device start-ups, and holds patents in medical instrumentation and physiological signal processing.

Mr. Barnes is a Trustee of Dedham Country Day School, is on the Board of Overseers of the MSPCA/Angell Animal Hospital, is a Corporation Member of Partners Healthcare, and is an Overseer of the Newton-Wellesley Hospital where he serves as a Trustee of its Charitable Foundation.  He has a B.S. degree in Physiology and Biophysics and an M.S. degree in Biomedical Engineering from Duke University, and an M.S. degree in Management from Stanford University.